Introduction
Synchronous primary endometrial and ovarian cancer (SPC) is frequently encountered in daily clinical settings. In 1985, Ulbright and Roth first reported the pathological criteria for distinguishing metastatic disease from SPC (1) . In 1995, Scully proposed more extensive criteria (2) , which are generally used when cancers develop both in the endometrium and in the ovary.
Zaino et al reported that SPC occurs in approximately 10% of women with ovarian cancer and 5% of women with endometrial cancer (3) . Earlier studies have suggested that there are other unique clinical features in SPC. Soliman et al reported that SPC patients are relatively young and nulliparous. The histology of SPC is mostly well-differentiated endometrioid adenocarcinoma, and its prognosis is better than that of primary uterine corpus cancer (PCC) with ovarian metastasis or primary ovarian cancer (POC) with uterus metastasis (4) .
The prevalence of pelvic endometriosis is approximately 6-10% in women (5) . It is estimated that the risk of ovarian cancer is considerably higher in the presence of endometriosis, particularly endometrioid adenocarcinoma and clear cell carcinoma of the ovary (6, 7) . Furthermore, certain reports have suggested a correlation between endometriosis and SPC (8) .
In this study, we reviewed 13 cases of SPC treated at our hospital, and compared their clinicopathological features with those of PCC and POC patients in our department. rence of cancer, overall survival rate and menstrual cycle (regular or irregular). Pathological information, including histology, grade and presence of endometriosis, were also obtained. Endometrial and ovarian cancer stages were assigned based on the classification by the International Federation for Gynecology and Obstetrics (FIGO). Histological determination of the endometrial and ovarian cancer was performed based on the World Health Organization (WHO) committee classification of tumors. A comparison of SPC with PCC and POC was performed for several clinical factors including age at diagnosis, BMI, parity and thrombosis complication.
Statistical analysis. The GraphPad prism (MDF Co., Japan) was used for the statistical analyses. Fisher's test was used to assess the significance of differences in the categorical clinical and pathological variables. Continuous variables were analyzed using the Mann-Whitney test. P<0.05 was considered to indicate a statistically significant difference.
Results
Patient characteristics. The characteristics of the SPC patients are listed in Table I . The mean age at diagnosis was 51.5 years, and the mean BMI was 22. Six of the 13 patients (46%) were nulliparous. Histologically, the lesion in the endometrium was endometrioid adenocarcinoma (G1/G2) in all cases, whereas the lesion in the ovary was well-differentiated endometrioid adenocarcinoma in 12 of 13 cases, and clear cell carcinoma in one case. The age at SPC diagnosis was significantly lower than the age at PCC diagnosis (51.5 vs. 58.9 years; Table II) . A greater number of SPC patients were nulliparous (46.2%) compared with the PCC (28.5%) and POC (33.8%) patients, although there was no significant difference. In our department, complete cytoreductive surgery with adjuvant chemotherapy is the standard treatment course for SPC. Recurrent disease was observed in two SPC patients. All patients, including those with disease recurrence, were alive as of January 2012. Endometriosis was observed in all of the SPC cases.
Comparison of young PCC and SPC patients. As the age of the SPC patients was significantly lower than that of PCC patients, we selected the young PCC patients (those under 45 years old) with G1 and G2 endometrioid adenocarcinoma, and compared them with the SPC patients in terms of the clinicopathological factors. The POC patients whose histological type was endometrioid adenocarcinoma or clear cell carcinoma were also used for comparison (Table III) . There was no significant difference between each group in terms of age, BMI and nulliparity. However, an irregular menstrual cycle was more frequently observed among the PCC patients under 45 years old than among the SPC patients (9 of 17, 52.9% vs. 2 of 13, 15.4%), although the difference was not significant (p= 0.05). In addition, endometriosis complications were more frequent among the SPC patients than the PCC patients under 45 years (17 of 17, 100% vs. 6 of 17, 35.3%). Moreover, the incidence of thrombosis was significantly higher in the SPC patients (7 of 13, 53.8% vs. none, 0%).
Incidence of thrombosis. Thrombosis complications were observed in SPC patients at a significantly higher frequency Table I . Characteristics of synchronous primary endometrial and ovarian cancer (SPC) patients. were also significantly older than those without thrombosis. In contrast, there was no significant difference in age and FIGO stage between the SPC patients with and without thrombosis. In addition, when the incidence of thrombosis was compared in advanced stage patients (FIGO stage II+III ovarian cancer or FIGO stage III endometrial cancer), the SPC patients had a significantly higher rate of thrombosis than the PCC (p<0.001) or POC (p=0.004) patients.
Discussion
In this study, we compared several clinicopathological features of SPC with those of PCC or POC. First, we found a significant difference in the age at diagnosis between patients with SPC and those with PCC. Patients with SPC were significantly younger than those with PCC (51.5 vs. 58.9 years). Additionally, the mean age of patients with SPC was relatively lower compared to POC, although the difference was not statistically significant.
In addition, patients with SPC exhibited a relatively high rate of nulliparity compared to those with PCC. There are several earlier reports that describe the clinicopathological features of SPC. In their review of 84 cases of SPC, Soliman et al reported that women with SPC were young, obese and nulliparous (4). Sultan et al also indicated that women with SPC were significantly younger than women with PCC and POC (9). Herrinton et al reported that high parity and long-term use of oral contraceptives reduced the risk of SPC (10) . Taken together, younger age and nulliparity appear to be unique features of SPC. Our next question was whether the difference between SPC and PCC is due to the inclusion of older PCC patients, who might be significantly different from younger patients in terms of tumor biology as well as host condition. To address this issue, we selected only the young PCC patients under the age of 45.
When the SPC patients were compared with this group of PCC patients, there were still significant differences: the incidence of endometriosis (100 vs. 35%) and thrombosis (54 vs. 0%) was significantly higher in SPC patients. These data suggest that SPC has several unique clinical features that are distinct from PCC in patients of a similar age. In all 13 SPC cases, the lesion in the endometrium was well-differentiated endometrioid carcinoma, and in 11 of the 13 cases, the lesion in the ovary was also well-differentiated endometrioid carcinoma. Of the other two SPC cases, one was clear cell carcinoma, and the other involved both well-differentiated endometrioid carcinoma and clear cell carcinoma in the ovary. According to previous reports, the majority of SPC cases consist of well-differentiated endometrioid carcinoma in both the endometrium and the ovary (4, 9, 11) , which is consistent with the results of the present study. In a relatively short follow-up period, only 2 (15.4%) cases of SPC recurred, and both patients are currently alive, suggesting a favorable outcome of SPC. Most of the previous reports refer to an excellent overall survival rate in women with SPC, which is reportedly due to the earlier stage at diagnosis of SPC compared with POC. The first symptom in the majority of SPC cases is abnormal bleeding (4) . Accordingly, in our study, 8 of the 13 SPC patients visited our hospital due to abnormal bleeding. However, Williams et al revealed that SPC still had a better prognosis that was independent of stage, even after adjusting for other prognosis factors. In other words, SPC itself might be directly associated with good prognosis (12) .
Notably, in our study, the presence of endometriosis was a factor in all the SPC patients. Endometriosis represents a significant site of origin of ovarian cancer, particularly in the case of endometrioid adenocarcinoma and clear cell carcinoma. Several previous reports have suggested a correlation between (14) . In our study, the clinicopathological features (irregular menstruation cycle and presence of endometriosis) of SPC resemble those of endometriosis-associated ovarian cancer rather than young-age PCC. In some of our SPC patients, atypical endometriosis was observed ( Fig. 1) , which is reportedly found in approximately 60-80% of endometriosis-associated ovarian cancer (8, 14) . Cancer-related thrombosis is also known as Trousseau's syndrome, which was first reported in 1865 in association with gastric cancer (15) . Factors secreted by cancer cells impair the coagulation and fibrinolytic system. One of these factors is tissue factor (TF) (16) . Conversion of factor VII to its active form (factor VIIa) in complex with TF triggers the production of other coagulation-related proteases, particularly factor X and factor IXa. Elevated TF expression is observed in carcinoma cells in Trousseau's syndrome as well as in associated angiogenic endothelium. Activated oncogenes (K-ras, EGFR, PML-RARA and MET) or inactivated tumor suppressors (p53 and PTEN) are known to lead to an induction of TF and its activity (17) . It is also suggested that tumor hypoxia increases the expression of genes that facilitate coagulation, including TF and plasminogen activator inhibitor type 1 (PAI-1) (18) . In gynecological malignancies, ovarian cancer, particularly clear cell carcinoma, is known to increase the development of complicated thrombosis (19, 20) . Uno et al studied TF activity in ovarian cancer, and reported that TF expression in clear cell carcinoma is significantly increased compared with that in non-clear cell carcinoma (21) . We demonstrated that clear cell carcinoma of the ovary has aberrant expression of coagulation-related genes, which is caused by the microenvironment within the endometriotic cyst (22) . Thus far, no study has addressed the association between SPC and thrombosis. In the current study, patients with SPC developed thromboses at a significantly higher rate compared to PCC and POC patients; as many as 53.8% (7 of 13) of the SPC patients developed complicated thrombosis prior to starting therapy. In the PCC and POC patients, those who developed thrombosis were significantly older than those who did not. In patients with PCC, those who developed thrombosis had a significantly higher FIGO stage than those who did not. However, in SPC cases, there was no such tendency. Although there was only a relatively small number of cases included in this study, SPC itself may be an independent risk factor for thrombosis, similar to clear cell carcinoma.
In conclusion, this study indicates that SPC has several unique features, including young age, nulliparity and a better prognosis. In addition, endometriosis was detected in all of the SPC patients, which is consistent with several previous studies. Clinically, SPC may be more similar to endometriosisrelated ovarian cancer than young-age corpus cancer. Notably, thrombosis occurred in patients with SPC at a significantly higher rate than in PCC and POC. There may be specific carcinogenetic mechanisms in SPC that are related to its own unique features, including the co-existence of endometriosis and thrombogenic tendency. Further research is required to explore these mechanisms.
